Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
Incyte's peak revenue was $4.2B in 2024. The peak quarterly revenue was $1.2B in 2024(q4).
Incyte's revenue increased from $169.9m in 2010 to $4.2B currently. That's a 2,396.63% change in annual revenue.
| Fiscal year / year | Incyte revenue |
|---|---|
| 2010 | $169.9M |
| 2011 | $94.5M |
| 2012 | $297.1M |
| 2013 | $354.9M |
| 2014 | $511.5M |
| 2015 | $753.8M |
| 2016 | $1.1B |
| 2017 | $1.5B |
| 2018 | $1.9B |
| 2019 | $2.2B |
| 2020 | $2.7B |
| 2021 | $3.0B |
| 2022 | $3.4B |
| 2023 | $3.7B |
| 2024 | $4.2B |
Rate Incyte's financial transparency
Incyte saw the greatest revenue growth in 2012, when revenue increased by 214.5%.
Incyte had the lowest revenue growth in 2011, when revenue changed by -44.4%.
| Year | Incyte growth |
|---|---|
| 2011 | -44%↓ |
| 2012 | 214%↑ |
| 2013 | 19%↑ |
| 2014 | 44%↑ |
| 2015 | 47%↑ |
| 2016 | 47%↑ |
| 2017 | 39%↑ |
| 2018 | 23%↑ |
| 2019 | 15%↑ |
| 2020 | 24%↑ |
| 2021 | 12%↑ |
| 2022 | 14%↑ |
| 2023 | 9%↑ |
| 2024 | 15%↑ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2010 | - | - | - | $85.9M |
| 2011 | $32.0M | $16.8M | $16.8M | $28.9M |
| 2012 | $36.2M | $86.5M | $60.5M | $113.8M |
| 2013 | $71.1M | $101.7M | $85.1M | $97.1M |
| 2014 | $89.8M | $99.6M | $198.1M | $124.0M |
| 2015 | $159.3M | $163.0M | $187.6M | $243.9M |
| 2016 | $263.5M | $246.3M | $269.5M | $326.5M |
| 2017 | $384.1M | $326.4M | $381.5M | $444.2M |
| 2018 | $382.3M | $521.5M | $449.7M | $528.4M |
| 2019 | $497.9M | $529.9M | $551.6M | $579.4M |
| 2020 | $568.5M | $688.0M | $620.6M | $789.5M |
| 2021 | $604.7M | $705.7M | $813.0M | $862.9M |
| 2022 | $733.2M | $911.4M | $823.3M | $926.7M |
| 2023 | $808.7M | $954.6M | $919.0M | $1.0B |
| 2024 | $880.9M | $1.0B | $1.1B | $1.2B |
Do you work at Incyte?
Is Incyte transparent about its revenue structure?
| CEO | Hervé Hoppenot |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 1,600 |
| Date Founded | 1991 |
| Headquarters | Wilmington, Delaware |
| Number of Locations | 1 |
| Revenue | $4.2B |
| Net Income | $340,660,000 |
| Gross Proft | $3.9B (2024) |
| PE Ratio | 541.04 |
| Tax Rate | 0.9% |
| Market Capitalization | $17.6B |
| Total Assets | $5,840,984,000 |
| Ticker | INCY |
Incyte's top competitor, Johnson & Johnson, earned an annual revenue of $88.8B.
Incyte's smallest competitor is Enzon Pharmaceuticals with revenue of $26.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 809 |
| Amgen | $93,349 | $33.4B | 22,000 | 678 |
| Merck | $90,328 | $64.2B | 74,000 | 1,567 |
| Zoetis | $87,092 | $9.3B | 11,300 | 300 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 303 |
| Johnson & Johnson | $76,686 | $88.8B | 134,500 | 1,985 |
| Seagen | $85,008 | $2.0B | 900 | - |
| Bristol-Myers Squibb | $101,824 | $48.3B | 30,000 | 2,309 |
| Eli Lilly and Company | $100,905 | $45.0B | 33,625 | 858 |
| Hoffmann-LA Roche Inc | $93,461 | $60.9B | 101,200 | 113 |
Zippia gives an in-depth look into the details of Incyte, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Incyte. The employee data is based on information from people who have self-reported their past or current employments at Incyte. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Incyte. The data presented on this page does not represent the view of Incyte and its employees or that of Zippia.
Incyte may also be known as or be related to Incyte, Incyte Corp. and Incyte Corporation.